RET and neuroendocrine tumors

Cancer Letters

Volumn 204, Issue 2, 2004, Pages 197-211

  Ichihara, Masatoshi ^a   Murakumo, Yoshiki ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cAMP; FMTC; FRS2; GDNF; GDNF family receptor ; Lamellidodia; Lipid rafts; Medullary thyroid carcinoma; MEN 2A; MEN 2B; Papillary thyroid carcinoma; Pheochromocytoma; Protein kinase A; Rai; RET; RET PTC; SHC; Signaling pathway; Tyrosine kinase

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN RET; PROTEIN TYROSINE KINASE; RAS PROTEIN; SYNAPTOPHYSIN;

ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE REARRANGEMENT; GERM LINE; GLIA CELL; HUMAN; INTESTINE INNERVATION; KIDNEY DEVELOPMENT; MISSENSE MUTATION; NERVE CELL; NERVE CELL DIFFERENTIATION; NEUROENDOCRINE TUMOR; NONHUMAN; NONSENSE MUTATION; PAPILLARY CARCINOMA; PARASYMPATHETIC NERVE; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; REVIEW; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; SURVIVAL RATE; THYROID CARCINOMA;

EID: 0842330656     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00456-7     Document Type: Article

References (130)

1. Takahashi M., Ritz J., Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 42:1985;581-588.
2. Takahashi M., Cooper G.M. Ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol. Cell Biol. 7:1987;1378-1385.
3. Takahashi M. Structure and expression of the ret transforming gene. IARC Sci. Publ. 1988;189-197.
4. Schuchardt A., D'Agati V., Larsson-Blomberg L., Costantini F., Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 367:1994;380-383.
5. Avantaggiato V., Dathan N.A., Grieco M., Fabien N., Lazzaro D., Fusco A., Simeone A., Santoro M. Developmental expression of the RET protooncogene. Cell Growth Differ. 5:1994;305-311.
6. Taraviras S., Marcos-Gutierrez C.V., Durbec P., Jani H., Grigoriou M., Sukumaran M., Wang L.C., Hynes M., Raisman G., Pachnis V. Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. Development. 126:1999;2785-2797.
7. Enomoto H., Crawford P.A., Gorodinsky A., Heuckeroth R.O., Johnson E.M. Jr., Milbrandt J. RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons. Development. 128:2001;3963-3974.
8. Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 60:1990;557-563.
9. Mulligan L.M., Kwok J.B., Healey C.S., Elsdon M.J., Eng C., Gardner E., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 363:1993;458-460.
10. Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2:1993;851-856.
11. Hofstra R.M., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367:1994;375-376.
12. Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., Wells S.A. Jr., Goodfellow P.J., Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl Acad. Sci. USA. 91:1994;1579-1583.
13. Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I., et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature. 367:1994;377-378.
14. Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S., Nihoul-Fekete C., Ponder B.A., Munnich A. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature. 367:1994;378-380.
15. Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 3:1988;571-578.
16. Takahashi M., Buma Y., Hiai H. Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene. 4:1989;805-806.
17. Iwamoto T., Taniguchi M., Asai N., Ohkusu K., Nakashima I., Takahashi M. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene. 8:1993;1087-1091.
18. Ishizaka Y., Itoh F., Tahira T., Ikeda I., Sugimura T., Tucker J., Fertitta A., Carrano A.V., Nagao M. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene. 4:1989;1519-1521.
19. Tahira T., Ishizaka Y., Itoh F., Sugimura T., Nagao M. Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene. 5:1990;97-102.
20. Myers S.M., Eng C., Ponder B.A., Mulligan L.M. Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene. 11:1995;2039-2045.
21. Treanor J.J., Goodman L., de Sauvage F., Stone D.M., Poulsen K.T., Beck C.D., Gray C., Armanini M.P., Pollock R.A., Hefti F., Phillips H.S., Goddard A., Moore M.W., Buj-Bello A., Davies A.M., Asai N., Takahashi M., Vandlen R., Henderson C.E., Rosenthal A. Characterization of a multicomponent receptor for GDNF. Nature. 382:1996;80-83.
22. Jing S., Wen D., Yu Y., Holst P.L., Luo Y., Fang M., Tamir R., Antonio L., Hu Z., Cupples R., Louis J.C., Hu S., Altrock B.W., Fox G.M. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell. 85:1996;1113-1124.
23. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
24. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson E.M. Jr., Milbrandt J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature. 384:1996;467-470.
25. Milbrandt J., de Sauvage F.J., Fahrner T.J., Baloh R.H., Leitner M.L., Tansey M.G., et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron. 20:1998;245-253.
26. Baloh R.H., Tansey M.G., Lampe P.A., Fahrner T.J., Enomoto H., Simburger K.S., Leitner M.L., Araki T., Johnson E.M. Jr., Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron. 21:1998;1291-1302.
27. Sanicola M., Hession C., Worley D., Carmillo P., Ehrenfels C., Walus L., Robinson S., Jaworski G., Wei H., Tizard R., Whitty A., Pepinsky R.B., Cate R.L. Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. Proc. Natl Acad. Sci. USA. 94:1997;6238-6243.
28. Creedon D.J., Tansey M.G., Baloh R.H., Osborne P.A., Lampe P.A., Fahrner T.J., Heuckeroth R.O., Milbrandt J., Johnson E.M. Jr. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc. Natl Acad. Sci. USA. 94:1997;7018-7023.
29. Baloh R.H., Tansey M.G., Golden J.P., Creedon D.J., Heuckeroth R.O., Keck C.L., Zimonjic D.B., Popescu N.C., Johnson E.M. Jr., Milbrandt J. TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron. 18:1997;793-802.
30. Jing S., Yu Y., Fang M., Hu Z., Holst P.L., Boone T., Delaney J., Schultz H., Zhou R., Fox G.M. GFRalpha-2 and GFRalpha-3 are two new receptors for ligands of the GDNF family. J. Biol. Chem. 272:1997;33111-33117.
31. Pachnis V., Mankoo B., Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development. 119:1993;1005-1017.
32. Tsuzuki T., Takahashi M., Asai N., Iwashita T., Matsuyama M., Asai J. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene. 10:1995;191-198.
33. Trupp M., Belluardo N., Funakoshi H., Ibanez C.F. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J. Neurosci. 17:1997;3554-3567.
34. Bennett D.L., Michael G.J., Ramachandran N., Munson J.B., Averill S., Yan Q., McMahon S.B., Priestley J.V. A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury. J. Neurosci. 18:1998;3059-3072.
35. Ikeda I., Ishizaka Y., Tahira T., Suzuki T., Onda M., Sugimura T., Nagao M. Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. Oncogene. 5:1990;1291-1296.
36. Santoro M., Rosati R., Grieco M., Berlingieri M.T., D'Amato G.L., de Franciscis V., Fusco A. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene. 5:1990;1595-1598.
37. Takahashi M., Buma Y., Taniguchi M. Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells. Oncogene. 6:1991;297-301.
38. Durbec P.L., Larsson-Blomberg L.B., Schuchardt A., Costantini F., Pachnis V. Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Development. 122:1996;349-358.
39. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3:2002;383-394.
40. de Graaff E., Srinivas S., Kilkenny C., D'Agati V., Mankoo B.S., Costantini F., Pachnis V. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev. 15:2001;2433-2444.
41. Lee D.C., Chan K.W., Chan S.Y. RET receptor tyrosine kinase isoforms in kidney function and disease. Oncogene. 21:2002;5582-5592.
42. Tsui-Pierchala B.A., Ahrens R.C., Crowder R.J., Milbrandt J., Johnson E.M. Jr. The long and short isoforms of Ret function as independent signaling complexes. J. Biol. Chem. 277:2002;34618-34625.
43. Borrello M.G., Mercalli E., Perego C., Degl'Innocenti D., Ghizzoni S., Arighi E., Eroini B., Rizzetti M.G., Pierotti M.A. Differential interaction of Enigma protein with the two RET isoforms. Biochem. Biophys. Res. Commun. 296:2002;515-522.
44. Ohiwa M., Murakami H., Iwashita T., Asai N., Iwata Y., Imai T., Funahashi H., Takagi H., Takahashi M. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B18 mutations. Biochem. Biophys. Res. Commun. 237:1997;747-751.
45. Asai N., Murakami H., Iwashita T., Takahashi M. A mutation at tyrosine 1062 in MEN 2A-Ret and MEN 2B-Ret impairs their transforming activity and association with shc adaptor proteins. J. Biol. Chem. 271:1996;17644-17649.
46. Borrello M.G., Alberti L., Arighi E., Bongarzone I., Battistini C., Bardelli A., Pasini B., Piutti C., Rizzetti M.G., Mondellini P., Radice M.T., Pierotti M.A. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol. Cell Biol. 16:1996;2151-2163.
47. Arighi E., Alberti L., Torriti F., Ghizzoni S., Rizzetti M.G., Pelicci G., Pasini B., Bongarzone I., Piutti C., Pierotti M.A., Borrello M.G. Identification of Shc docking site on Ret tyrosine kinase. Oncogene. 14:1997;773-782.
48. Lorenzo M.J., Gish G.D., Houghton C., Stonehouse T.J., Pawson T., Ponder B.A., Smith D.P. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. Oncogene. 14:1997;763-771.
49. Alberti L., Borrello M.G., Ghizzoni S., Torriti F., Rizzetti M.G., Pierotti M.A. Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene. 17:1998;1079-1087.
50. Durick K., Gill G.N., Taylor S.S. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Mol. Cell Biol. 18:1998;2298-2308.
51. Pandey A., Duan H., Di Fiore P.P., Dixit V.M. The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10. J. Biol. Chem. 270:1995;21461-21463.
52. van Weering D.H., Bos J.L. Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res. 154:1998;271-281.
53. van Weering D.H., Medema J.P., van Puijenbroek A., Burgering B.M., Baas P.D., Bos J.L. Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. Oncogene. 11:1995;2207-2214.
54. Worby C.A., Vega Q.C., Zhao Y., Chao H.H., Seasholtz A.F., Dixon J.E. Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J. Biol. Chem. 271:1996;23619-23622.
55. van Weering D.H., Bos J.L. Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation. J. Biol. Chem. 272:1997;249-254.
56. Xing S., Furminger T.L., Tong Q., Jhiang S.M. Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells. J. Biol. Chem. 273:1998;4909-4914.
57. Chiariello M., Visconti R., Carlomagno F., Melillo R.M., Bucci C., de Franciscis V., Fox G.M., Jing S., Coso O.A., Gutkind J.S., Fusco A., Santoro M. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene. 16:1998;2435-2445.
58. Murakami H., Iwashita T., Asai N., Iwata Y., Narumiya S., Takahashi M. Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase. Oncogene. 18:1999;1975-1982.
59. Murakami H., Iwashita T., Asai N., Shimono Y., Iwata Y., Kawai K., Takahashi M. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signaling molecules mediated by ret with the MEN 2B mutation. Biochem. Biophys. Res. Commun. 262:1999;68-75.
60. Melillo R.M., Barone M.V., Lupoli G., Cirafici A.M., Carlomagno F., Visconti R., Matoskova B., Di Fiore P.P., Vecchio G., Fusco A., Santoro M. Ret-mediated mitogenesis requires Src kinase activity. Cancer Res. 59:1999;1120-1126.
61. Trupp M., Scott R., Whittemore S.R., Ibanez C.F. Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J. Biol. Chem. 274:1999;20885-20894.
62. Soler R.M., Dolcet X., Encinas M., Egea J., Bayascas J.R., Comella J.X. Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons. J. Neurosci. 19:1999;9160-9169.
63. Feng L., Wang C.Y., Jiang H., Oho C., Dugich-Djordjevic M., Mei L., Lu B. Differential signaling of glial cell line-derived neurothrophic factor and brain-derived neurotrophic factor in cultured ventral mesencephalic neurons. Neuroscience. 93:1999;265-273.
64. Segouffin-Cariou C., Billaud M. Transforming ability of MEN 2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J. Biol. Chem. 275:2000;3568-3576.
65. Hayashi H., Ichihara M., Iwashita T., Murakami H., Shimono Y., Kawai K., Kurokawa K., Murakumo Y., Imai T., Funahashi H., Nakao A., Takahashi M. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene. 19:2000;4469-4475.
66. Besset V., Scott R.P., Ibanez C.F. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J. Biol. Chem. 275:2000;39159-39166.
67. De Vita G., Melillo R.M., Carlomagno F., Visconti R., Castellone M.D., Bellacosa A., Billaud M., Fusco A., Tsichlis P.N., Santoro M. Tyrosine 1062 of RET-MEN 2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res. 60:2000;3727-3731.
68. Califano D., Rizzo C., D'Alessio A., Colucci-D'Amato G.L., Cali G., Bartoli P.C., Santelli G., Vecchio G., de Franciscis V. Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells. J. Biol. Chem. 275:2000;19297-19305.
69. Hayashi Y., Iwashita T., Murakamai H., Kato Y., Kawai K., Kurokawa K., Tohnai I., Ueda M., Takahashi M. Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN 2A mutation. Biochem. Biophys. Res. Commun. 281:2001;682-689.
70. Pelicci G., Troglio F., Bodini A., Melillo R.M., Pettirossi V., Coda L., De Giuseppe A., Santoro M., Pelicci P.G. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol. Cell Biol. 22:2002;7351-7363.
71. O'Bryan J.P., Songyang Z., Cantley L., Der C.J., Pawson T. A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. Proc. Natl Acad. Sci. USA. 93:1996;2729-2734.
72. Sakai R., Henderson J.T., O'Bryan J.P., Elia A.J., Saxton T.M., Pawson T. The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons. Neuron. 28:2000;819-833.
73. Brown D.A., London E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell. Dev. Biol. 14:1998;111-136.
74. Anderson R.G. The caveolae membrane system. Annu. Rev. Biochem. 67:1998;199-225.
75. Tooze S.A., Martens G.J., Huttner W.B. Secretory granule biogenesis: rafting to the SNARE. Trends Cell Biol. 11:2001;116-122.
76. Wolozin B. A fluid connection: cholesterol and Abeta. Proc. Natl Acad. Sci. USA. 98:2001;5371-5373.
77. Poteryaev D., Titievsky A., Sun Y.F., Thomas-Crusells J., Lindahl M., Billaud M., Arumae U., Saarma M. GDNF triggers a novel ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor alpha1. FEBS Lett. 463:1999;63-66.
78. Tansey M.G., Baloh R.H., Milbrandt J., Johnson E.M. Jr. GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron. 25:2000;611-623.
79. Paratcha G., Ledda F., Baars L., Coulpier M., Besset V., Anders J., Scott R., Ibanez C.F. Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron. 29:2001;171-184.
80. Engele J., Franke B. Effects of glial cell line-derived neurotrophic factor (GDNF) on dopaminergic neurons require concurrent activation of cAMP-dependent signaling pathways. Cell Tissue Res. 286:1996;235-240.
81. Hanson M.G. Jr., Shen S., Wiemelt A.P., McMorris F.A., Barres B.A. Cyclic AMP elevation is sufficient to promote the survival of spinal motor neurons in vitro. J. Neurosci. 18:1998;7361-7371.
82. Cai D., Shen Y., De Bellard M., Tang S., Filbin M.T. Prior exposure to neurotrophins blocks inhibition of axonal regeneration by MAG and myelin via a cAMP-dependent mechanism. Neuron. 22:1999;89-101.
83. Song H.J., Ming G.L., Poo M.M. cAMP-induced switching in turning direction of nerve growth cones. Nature. 388:1997;275-279.
84. Fukuda T., Kiuchi K., Takahashi M. Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. J. Biol. Chem. 277:2002;19114-19121.
85. Krieglstein K., Henheik P., Farkas L., Jaszai J., Galter D., Krohn K., Unsicker K. Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons. J. Neurosci. 18:1998;9822-9834.
86. Schober A., Hertel R., Arumae U., Farkas L., Jaszai J., Krieglstein K., Saarma M., Unsicker K. Glial cell line-derived neurotrophic factor rescues target-deprived sympathetic spinal cord neurons but requires transforming growth factor-beta as cofactor in vivo. J. Neurosci. 19:1999;2008-2015.
87. Peterziel H., Unsicker K., Krieglstein K. TGFbeta induces GDNF responsiveness in neurons by recruitment of GFRalpha1 to the plasma membrane. J. Cell. Biol. 159:2002;157-167.
88. Tsui-Pierchala B.A., Milbrandt J., Johnson E.M. Jr. NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons. Neuron. 33:2002;261-273.
89. Jhiang S.M. The RET proto-oncogene in human cancers. Oncogene. 19:2000;5590-5597.
90. Salassidis K., Bruch J., Zitzelsberger H., Lengfelder E., Kellerer A.M., Bauchinger M. Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma. Cancer Res. 60:2000;2786-2789.
91. Klugbauer S., Jauch A., Lengfelder E., Demidchik E., Rabes H.M. A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8). Cancer Res. 60:2000;7028-7032.
92. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 12:2001;361-373.
93. Gimm O. Thyroid cancer. Cancer Lett. 163:2001;143-156.
94. Castellone M.D., Cirafici A.M., De Vita G., De Falco V., Malorni L., Tallini G., Fagin J.A., Fusco A., Melillo R.M., Santoro M. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene. 22:2003;246-255.
95. Baldassarre G., Bruni P., Boccia A., Salvatore G., Melillo R.M., Motti M.L., Napolitano M., Belletti B., Fusco A., Santoro M., Viglietto G. Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). Oncogene. 21:2002;1739-1749.
96. Eng C. RET proto-oncogene in the development of human cancer. J. Clin. Oncol. 17:1999;380-393.
97. Mulligan L.M., Marsh D.J., Robinson B.G., Schuffenecker I., Zedenius J., Lips C.J., et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J. Intern. Med. 238:1995;343-346.
98. Eng C., Clayton D., Schuffenecker I., Lenoir G., Cote G., Gagel R.F., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 276:1996;1575-1579.
99. Hoppner W., Ritter M.M. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum. Mol. Genet. 6:1997;587-590.
100. Hoppner W., Dralle H., Brabant G. Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. Hum. Mutat. (Suppl 1):1998;S128-S130.
101. Pigny P., Bauters C., Wemeau J.L., Houcke M.L., Crepin M., Caron P., Giraud S., Calender A., Buisine M.P., Kerckaert J.P., Porchet N. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 84:1999;1700-1704.
102. Miyauchi A., Futami H., Hai N., Yokozawa T., Kuma K., Aoki N., Kosugi S., Sugano K., Yamaguchi K. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J. Cancer Res. 90:1999;1-5.
103. Iwashita T., Murakami H., Kurokawa K., Kawai K., Miyauchi A., Futami H., Qiao S., Ichihara M., Takahashi M. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. Biochem. Biophys. Res. Commun. 268:2000;804-808.
104. Asai N., Iwashita T., Matsuyama M., Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell Biol. 15:1995;1613-1619.
105. Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science. 267:1995;381-383.
106. Borrello M.G., Smith D.P., Pasini B., Bongarzone I., Greco A., Lorenzo M.J., et al. RET activation by germline MEN 2A and MEN 2B mutations. Oncogene. 11:1995;2419-2427.
107. Iwashita T., Asai N., Murakami H., Matsuyama M., Takahashi M. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN 2A or MEN 2B mutation. Oncogene. 12:1996;481-487.
108. Rossel M., Pasini A., Chappuis S., Geneste O., Fournier L., Schuffenecker I., Takahashi M., van Grunsven L.A., Urdiales J.L., Rudkin B.B., Lenoir G.M., Billaud M. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene. 14:1997;265-275.
109. Ito S., Iwashita T., Asai N., Murakami H., Iwata Y., Sobue G., Takahashi M. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res. 57:1997;2870-2872.
110. Pasini A., Geneste O., Legrand P., Schlumberger M., Rossel M., Fournier L., Rudkin B.B., Schuffenecker I., Lenoir G.M., Billaud M. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene. 15:1997;393-402.
111. Iwashita T., Kato M., Murakami H., Asai N., Ishiguro Y., Ito S., Iwata Y., Kawai K., Asai M., Kurokawa K., Kajita H., Takahashi M. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene. 18:1999;3919-3922.
112. Carlomagno F., Salvatore G., Cirafici A.M., De Vita G., Melillo R.M., de Franciscis V., Billaud M., Fusco A., Santoro M. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res. 57:1997;391-395.
113. Ponder B.A., Smith D. The MEN II syndromes and the role of the ret proto-oncogene. Adv. Cancer Res. 70:1996;179-222.
114. Zhou S., Carraway K.L. III, Eck M.J., Harrison S.C., Feldman R.A., Mohammadi M., et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 373:1995;536-539.
115. Bocciardi R., Mograbi B., Pasini B., Borrello M.G., Pierotti M.A., Bourget I., Fischer S., Romeo G., Rossi B. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene. 15:1997;2257-2265.
116. Watanabe T., Ichihara M., Hashimoto M., Shimono K., Shimoyama Y., Nagasaka T., Murakumo Y., Murakami H., Sugiura H., Iwata H., Ishiguro N., Takahashi M. Characterization of gene expression induced by RET with MEN 2A or MEN 2B mutation. Am. J. Pathol. 161:2002;249-256.
117. Murakami H., Yamamura Y., Shimono Y., Kawai K., Kurokawa K., Takahashi M. Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J. Biol. Chem. 277:2002;32781-32790.
118. O'Riordain D.S., O'Brien T., Crotty T.B., Gharib H., Grant C.S., van Heerden J.A. Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery. 118:1995;936-942.
119. Wells S.A. Jr., Dilley W.G., Farndon J.A., Leight G.S., Baylin S.B. Early diagnosis and treatment of medullary thyroid carcinoma. Arch. Intern. Med. 145:1985;1248-1252.
120. Sherman S.I., Gagel R.F. Neoplastic disorders affecting multiple endocrine organs. Braunwald E. Harrison's Principles of Internal Medicine. 15th ed. 2001;2184-2189 McGraw-Hill, New York, USA.
121. Utiger R.D. Medullary thyroid carcinoma, genes, and the prevention of cancer. N. Engl. J. Med. 331:1994;870-871.
122. Gagel R.F., Tashjian A.H. Jr., Cummings T., Papathanasopoulos N., Kaplan M.M., DeLellis R.A., Wolfe H.J., Reichlin S. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N. Engl. J. Med. 318:1988;478-484.
123. Snow K.J., Boyd A.E. III. Management of individual tumor syndromes. Medullary thyroid carcinoma and hyperparathyroidism. Endocrinol. Metab. Clin. North Am. 23:1994;157-166.
124. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
125. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
126. Okuda K., Weisberg E., Gilliland D.G., Griffin J.D. ARG tyrosine kinase activity is inhibited by STI571. Blood. 97:2001;2440-2448.
127. Cohen M.S., Hussain H.B., Moley J.F. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery. 132:2002;960-966. discussion 966-967.
128. Carlomagno F., Vitagliano D., Guida T., Napolitano M., Vecchio G., Fusco A., Gazit A., Levitzki A., Santoro M. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 62:2002;1077-1082.
129. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., Ryan A.J., Fontanini G., Fusco A., Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62:2002;7284-7290.
130. Saarma M. GDNF recruits the signaling crew into lipid rafts. Trends Neurosci. 24:2001;427-429.